Skip to content

Targeting Neuroplasticity for Persistent Post-Concussive Cognitive Symptoms

Targeting Neuroplasticity for Persistent Post-Concussive Cognitive Symptoms: A Trial of tDCS and Cognitive Training 3-12 Months Post-mTBI

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07246993
Enrollment
30
Registered
2025-11-25
Start date
2026-03-05
Completion date
2028-01-01
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Traumatic Brain Injury, Persistent Post Concussion Syndrome

Brief summary

This project investigates an innovative combination of non-invasive neuromodulation (transcranial direct current stimulation - tDCS) and cognitive training as a novel treatment approach aimed at improving function in individuals suffering from persistent post-concussive syndrome (PPCS) following mild traumatic brain injury (mTBI).

Interventions

DEVICEActive tDCS

All participants will receive 10 sessions of cognitive training focused on executive functions, delivered over approximately 3 weeks. Cognitive training will be completed on a lab provided computer using PositScience BrainHQ or TaskFlow software. Concurrently, during each training session, participants will receive either active or sham tDCS. Stimulation will be delivered via saline-soaked sponge electrodes using the Soterix 1x1 miniCT TES device. The anode (active electrode) will be placed over the L-DLPFC (approximated by EEG coordinate F3) and the cathode (reference electrode) over the contralateral supraorbital area (Fp2). The active tDCS group will receive 2mA constant current for 20 minutes.

DEVICESham tDCS

All participants will receive 10 sessions of cognitive training focused on executive functions, delivered over approximately 3 weeks. Cognitive training will be completed on a lab provided computer using PositScience BrainHQ or TaskFlow software. Concurrently, during each training session, participants will receive either active or sham tDCS. Stimulation will be delivered via saline-soaked sponge electrodes using the Soterix 1x1 miniCT TES device. The anode (active electrode) will be placed over the L-DLPFC (approximated by EEG coordinate F3) and the cathode (reference electrode) over the contralateral supraorbital area (Fp2). The sham tDCS group will receive a brief ramp up and ramp down of current at the beginning and end of the 20 minutes to mimic the sensation of active stimulation.

Sponsors

University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

double-blind, randomized, sham-controlled clinical trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-65 * Has sustained a single mTBI 3-12 months prior to enrollment * Meets criteria for PPCS (assessed using the CP Screen) * Has reliable access to a smartphone

Exclusion criteria

* Inability to provide informed consent or complete study procedures * History of moderate/severe TBI * Significant neurological or psychiatric disorders (other than PPCS-related symptoms like mild depression/anxiety) * Substance dependence within the last six months * Contraindications to tDCS (e.g., implanted metal, skin lesions on scalp)

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of active tDCS combined with cognitive training compared to sham tDCS combined with cognitive training for improving executive function in individuals with PPCSWeek 4Using score on Penn Cognitive Battery

Secondary

MeasureTime frameDescription
Effects of active versus sham tDCS combined with cognitive training on self-reported affect, stress, cognition, and objectively measured sleep and activity levelsWeek 4Ecological Momentary Assessment Survey score

Countries

United States

Contacts

CONTACTMelanie Stimac
stima011@umn.edu612-301-2549
PRINCIPAL_INVESTIGATORJazmin Camchong, PhD

University of Minnesota

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026